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A study was conducted to determine the immune status of dogs vaccinated against Canine Parvovirus 
(CPV) and Canine Distemper Virus (CDV) by a clinic-based immunoblot enzyme-linked immunosorbent 
assay (ELISA) using a commercially available 120 sample immunocomb® test kit for canine parvo and 
distemper IgG  in Benin City, Nigeria. Out of 120 dogs sampled, 63 (52.5%) were females while 57 
(47.5%) were males. 84 (70%) dogs were exotic breeds while 36 (30%) were mongrels. Majority of the 
dogs (35, 29.17%) were less than one year old and the age range of all dogs sampled was between 9 
weeks and 10 years. Analysis of data showed that there was no significant difference (P < 0.05) between 
sex, breed, age and level of immunity. A non-parametric chi-square contingency analysis of antigens 
(CPV and CDV) and level of immunity revealed that there was a high significant association (p < 0.001) 
between CPV and CDV antigens and level of immunity of the vaccinated dogs sampled.  
 





Canine distemper is a highly contagious, multi-systemic, 
and potentially fatal viral disease that was once recog-
nized as the leading cause of death in dogs. It affects pri-
marily dogs and several other animals’ species including 
of recent members of the Felidae family - lions and tigers, 
both in nature and in captivity (Morell, 1994; Harder et al., 
1996; Roelke-Parker et al., 1996). It is an enzootic disea-
se with a wide host range and has been reported in most 
parts of the world including Nigeria (Abdullahi, 1979). The 
disease is caused by a canine distemper virus (CDV), 
which is a member of the genus morbillivirus in the Para-
myxoviridae family. The virus is antigenically related to 
human measles virus (HMV), rinderpest virus, peste-
depetits ruminant virus (PPRV) and dolphin distemper 
virus (Appel, 2000). The control of the disease has been 
throu-gh annual vaccinations in dogs especially in those 
coun-tries where prophylaxis has only been limited to the 
reduction of incidence (Appel and Summers, 1999). 
In recent years, the incidence of distemper in dogs app-
ears to have increased despite the significant strides 
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the use of modified-live CDV vaccines and the develop-
ment of several diagnostic tests for specific viral diag-
nosis. Waner et al. (1998) reported that the persistence 
of canine distemper is as a result of insufficient vaccine-
tions in cases where multiple vaccinations are a common 
practice and or vaccination failures probably due to faulty 
vaccine and interference by maternally derived antibody 
(MDA).  
Canine parvovirus (CPV) like CDV is also a contagious 
disease of dogs and other Canidae such as wolves, coy-
otes, Smith American dogs and Asiatic Raccoon dogs. It 
is an important cause of mortality and morbidity in young 
dogs (Waner et al., 2004). The virus is a widespread, 
resistant and highly contagious agent capable of causing 
enteritis and myocarditis and is excreted in faeces both in 
naturally infected and vaccinated dogs (Brunner and 
Swango 1985). The disease is both controlled by mono-
valent and multivalent vaccines. However, sporadic cas-
es do occur particularly in the young population when ini-
tial vaccinations fail because of interference by mater-
nally derived antibodies (MDA) (Waner et al., 2004). 
Interference by maternally derived antibodies is regar-
ded as a major cause of Canine Parvovirus and Canine 
distemper virus vaccination failures in young dogs (Baker 
et al., 1959; Pollock and CarMichael, 1982; Buonavoglia 






the conclusion that the surest way to know that a puppy 
has adequately responded to vaccination or to confirm 
the immune status in a mature dog is to check the anti-
body levels in the dog’s blood or serum. An easily acces-
sible in-clinic procedure called immunoblot ELISA assay 
(rapid dot-ELISA assay or immunocomb ELISA test) has 
been developed for the semi-quantitative assay of CDV 
and CPV IgG antibody titres in the sera of vaccinated 
mature and young dogs using the enzyme-linked immu-
nosorbent assay (ELISA) technology (Naveh et al., 1995; 
Waner et al., 1996; Waner et al., 1998; Truyen, 2001). 
In Benin City there have been several records of mor-
talities and morbidities in dogs despite immunization. Cli-
nical records revealed that these dogs manifested high 
fever, vomiting, diarrhea and weakness as common 
signs. In this study, the Biogal’s Immunocomb(R) antibody 
test kit for canine parvovirus and distemper IgG was used 








One hundred and twenty (120) dogs of both sexes; females (63, 
52.50%) and males (57, 47.5%), of different ages; less than one 
year (35, 29.17%), 1-2 years (31, 25.83%), 3-4 years (32, 26.67%), 
5 - 6 years (10, 8.33%), 7 - 8 years (10, 8.33%) and 9 – 10 years 
(2, 1.67%) and intervals since last vaccination were enrolled in this 
study. Seventy (53.33%) of the dogs were owned by clients where 
they were being maintained under domestic setting and assessed 
under conditions encountered in every day life. Nineteen (15.83%) 
were clinic-owned and thirty-one (25.83%) were those raised by 
breeders where they were maintained under relatively controlled 
conditions. Selection for studies was done based on thorough eval-
uation of individual dog medical records of routine clinic visits and 
vaccinations for two and half (2½) years (between November, 2003 
and May, 2006) in Benin City, Nigeria.  
 
 
Serum collection and storage 
 
Blood was collected from the cephalic vein of each dog on 
presentation. Injection sites were aseptically prepared using swabs 
soaked in methylated spirit. Each blood sample was transferred to a 
sterile, non-heparinized plastic test tube and kept on a slanting 
position at 45C under room temperature of 20 – 25C and left 
overnight to allow for proper clotting. Sera, which were collected 
from the 120 dogs sampled, were centrifuged (Sigma Ultra 
centrifuge, USA) at 2500 rpm for 5 min for purification and stored at 
–20C. The processing of the serum samples was carried out at the 
Department of Medical Microbiology (Virology unit) of the University 





A multivalent vaccine (Duramine® Forte Dudge Animal Health, Forte 
Dodge, IOWA, USA) containing Modified-live Distemper, Parvo, 
Leptospira, Canine Adenovirus and Parainfluenza antigen was 
used prior to sampling. Vaccination schedule employed in the area 
of study (Benin City) indicated that dogs received their primary 
vaccination at 6, 10 and 14 weeks old, then annual revaccination 
using this vaccine. Out of the 120 dogs  sampled,  29  (24.17%)  did 




not receive any of the primary vaccination, 47 (39.17%) received 
single primary vaccination, 11 (9.17%) received double primary vac-
cination, 32 (26.6%) received triple primary vaccination while one 
(0.83%) was not documented. For the annual revaccination, 39 
(32.52%) did not receive any annual revaccination, 25 (20.83%) 
received single, 33 (27.50%), received double and 16 (13.33%) re-






A 120 sample immunocomb® test kit for canine distemper and 
parvo IgG (immunocomb biogal laboratories Kibbutz Galed, Israel) 
was used for the evaluation of CPV and CDV IgG antibodies in sera 
of dogs collected using the Immunoblot Enzyme-linked Immunosor-
bent Assay (ELISA) method. It is a semi quantitative procedure 
based on color comparison between a standard and a test sample 





The test of association between types of antigens (CPV and CDV) 
and level of immunity was measured by a non-parametric chi-sq-
uare contingency analysis at 95% level of confidence and values of 





The data of the 120 dogs examined for 2½ years (from 
November, 2003 to May, 2006) and results of the immu-
nocomb test performed on the samples collected, sum-
mary of results of the test performed and the result of the 
test association between types of antigens (CPV and 
CDV) and level of immunity were represented in the data 
provided. Both sex and breed showed no statistical 
significant difference (P > 0.05) with level of immunity 
against both CPV and CDV. However, in this study there 
was a significant difference (P < 0.05) between age and 
level of immunity to CDV. Both sexes showed high levels 
of immunity (high IgG titer ranging from 1:80 – 1:640) to 
both CPV and CDV antigens (Figures 1 and 2). The age 
of dogs ranged from 9 weeks to 10 years with the 
majority of dogs less than one year 35 (29.17%). All ages 
of dogs sampled showed significant levels of IgG titres, 
ranging from 1:80 – 1:640 to both CPV and CDV antigens 
(at P < 0.05) as shown in (Figures 3 and 4). Alsatian 
breeds of dogs were sampled more followed by the 
mongrel breed. All breeds showed remarkable levels of 
IgG titres (ranging from 1:80 – 1:640) to both CPV and 
CDV antigens as shown in Figures 5 and 6.  
Out of the total number of dogs sampled, 47 (39.17%) 
dogs received single primary vaccination at either 6, 10 
or 14 weeks while 39 (32.5%) dogs did not receive any or 
all of the total annual revaccinations up to the time of 
sampling. Figures 7 and 8 showed the level of immunity 
and total annual revaccinations. These results indicated 
that some of the dogs showed high level of immunity (at 
value of 1:80 – 1:640) despite not being revaccinated 
while some did not show some level of immunity (at value 
of 0 – 1:20) despite being revaccinated. 
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Figure 3. Relationship between Age and level of immunity to CPV. 
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Figure 6. Relationship between breed and level of immunity to CDV. 
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Figure 7. Relationship between total primary vaccination and number of dogs sampled. NV = Not 
vaccinated, SPV = single primary vaccination, DPV = double primary vaccination, TPV = triple 
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Figure 8. Relationship between total annual revaccination and number of dogs sampled. NV = Not 
vaccinated, SPV = single primary vaccination, DPV = double primary vaccination, TPV = triple primary 




All dogs sampled gave significant levels of antibody titre 
(P < 0.05) to both CPV and CDV antigens following im-
munocomb IgG antibody assay. However, there was a 
higher titer to CPV (with titre values of up to 1:640) than 
CDV following evaluation and analysis of results. A Chi 
Square t-test showed that there was a significant asso-
ciation (P < 0.05) between CPV and CDV antigens and 
level of immunity (with titre values ranging from 1:80 – 





Results obtained from this study provided evidence that 
dogs vaccinated against CPV and CDV using commer-
cially available CPV and CDV combination vaccine sho-
wed and maintained protective antibody titers. In this 
area of study, both CPV and CDV are endemic and are a 
cause of clinically important diseases in dogs associated 
with high mortality and morbidity rates. This correlated 
well with what was reported in literature (Abdullahi, 
1979). Investigation of immune status following vaccina-
tion using standard procedures like the hemagglutination 
inhibition (HI), serum neutralization (SN) and immunofluo-
rescent antibody (IFA) has not been practicable in Nigeria 
in view of the cost and other limitations associated with 
these tests (such as trained personnel and time cons-
traint) as has been the case even in some advanced 






1998; Waner et al., 2004). Thus, the use of a rapid in-
clinic immunoblot ELISA technique for the semi quanti-
tative analyses of antibody titers to CPV and CDV provi-
des solution to this limitation. This technique has been 
used to assess antibody response of pups after primary 
vaccination and the persistence of serum antibody titers 
to specific infectious diseases in adult dogs as revealed 
in literature (Naveh et al., 1995; Waner et al., 1996; 
Tizzard and Yawie, 1998 Waner et al., 2002; Waner et 
al., 2003; Waner and Keren-Kornblatt, 2006). 
In this study, data was collected from 120 dogs of dif-
ferent sexes, ages and breeds so as to give a broader 
picture of dogs’ antibody response to vaccination. Find-
ings revealed that, some dogs were not vaccinated but 
showed some level of antibody against CPV and CDV as 
shown in Figures 7 and 8. Antibodies detected in this 
case must have been generated as a result of natural 
exposure to CPV and CDV antigens. This is common in 
mongrel breed of dogs (Figures 5 and 6) that stray or 
kept by owners that are either ignorant or not willing to 
present their pets for immunizations as revealed in litera-
ture (Waner et al., 1996) and personal experience. Con-
versely, some dogs showed no antibody despite vaccina-
tion (Figures 7 and 8). This is attributable to the fact that, 
there was vaccination failure. Reports have revealed that 
vaccine failure can result from the effect of maternally 
derived antibody or passively acquired antibodies at time 
of vaccination, delay in maturation of the immune system, 
poor vaccinal immunogenicity, genetic inability to respond 
to certain vaccine antigens, immuno suppression and 
ineffective lots of vaccine (Tizzard and Yawei, 1998; 
Schultz, 2000; Wise et al., 2006). It has also been repor-
ted that some dogs never appeared to mount an ade-
quate antibody response to vaccination, but still remained 
healthy (Twark and Dodds, 2000). This is as a result of 
the persistence of immune memory cells and cell-media-
ted and mucosal immunity. It is thus advocated that 
revaccination is not required in this scenario. If however, 
there is low antibody response to vaccination due to vac-
cination failure as indicated abov, revaccination may be 
required. In such a case, the use of immunoblot ELISA 
assay in determining when to vaccinate dogs will be 
significant. 
It was found that dog breeders in Benin City do not 
vaccinate their puppies particularly with the initial dose of 
primary vaccination that is usually administered at 6 
week. This is to maximize their profits. Prospective puppy 
buyers are therefore saddled with the responsibility of va-
ccinating their newly acquired puppies. Also, most pet 
owners in this area acquire puppies as from 8 - 10 weeks 
of age when they must have been due for the second 
dose of primary vaccinations. The data presented indica-
ted high number of dogs 39 (32.5%) that never received 
any of the booster doses (annual revaccination). This is 
as a result of the fact that most pet owners whose dogs 
were due for first booster failed to turn up after the third 
dose   of   primary   vaccinations.  In  the  same  data,  32  




(26.7%) of the dogs were not due for annual revaccina-
tion as at time of sampling.  
All breeds show remarkable levels of IgG titers to both 
CPV and CDV antigens as seen in Figures 5 and 6. How-
ever records in the data of dogs sampled showed that 
immunizations were more in exotic than in mongrel bre-
eds of dogs. In Benin City, medical records have revea-
led that exotic breeds of dogs are mostly owned by the 
elites, high-income earners (affluent) and security com-
panies that utilize dogs in providing their services. These 
categories of dog owners provide better environments for 
keeping dogs, provide high quality diets to their pets and 
can afford to pay veterinary hospital bills. Mongrel breed 
of dogs however, do not enjoy any of such incentives and 
their owners are either low-income earners or ignorant of 
better pet care. 
All sexes (Figures 1 and 2) and breeds (Figures 5 and 
6) of dogs sampled showed no significant association (P 
< 0.05) with adequate CPV and CDV serum antibody 
titers but there was a significant association (P < 0.05) 
between CDV and level of immunity using the Chi-Square 
t-test. Earlier work by Twark and Dodds (2000) reported 
that sex, age and breed showed no significant associa-
tion (where P > 0.05) with CPV and CDV serum antibody 
titer. However, in this study there was a significant asso-
ciation between age and CDV serum antibody titer. This 
may either be due to the fact that most dogs sampled 
were less than 1 year old or because of the labile and 
environmentally unstable nature of CDV. The effect of 
maternally derived antibodies on the young population of 
dogs mostly sampled in this study and the nature of CDV 
can result in low or unsustainable immunity over a given 
period of time. This is also in agreement with what was 
reported in the literatures (Waner, 2004; Waner et al., 
2004; Waner and Keren-Kornblatt, 2006). 
Results obtained from this study also revealed that IgG 
titers were detected from some dogs months to years 
after vaccinations. This provided the evidence that vacci-
nations of dogs with a commercially available combina-
tion vaccine containing modified-live CPV and CDV 
antigens confer and maintains adequate immunity for up 
to 3 or more years as revealed in literature (Tizzard and 
Yawei Ni, 1998; Schultz, 1999; Schultz, 2000; Twark and 
Dodds, 2000; Douglas et al., 2004; Gill et al., 2004; 
Waner, 2004; Waner and Keren-Kornblatt, 2006). 
Results of immunocomb assay presented in the data 
showed that antibody response to CPV was higher than 
that of CDV (where there was significant S values of 3 –6 
in CPV than CDV). CPV is stable in the environment. 
Natural boosting of immunity and thus sustained protec-
tive antibody become possible. CDV on the other hand is 
labile and susceptible to the environment. Immunity indu-
ced tends to be relatively lower than in CPV. This is in 
conformity with what was reported in literature (Waner et 
al., 2004; Waner, 2004; Waner and Keren-Kornblatt, 
2006). The test of hypothesis at P < 0.05 confirmed that 
there was a high significant association between  level  of  
 




immunity and vaccination against CPV and CDV antigens 
(p < 0.0001).  
 
 
Conclusion and recommendation  
 
This present study clearly confirms post-vaccination im-
munity for canine distemper and parvoviral fractions in a 
commercial multivalent modified-Live virus vaccine. Rou-
tine serological testing has since been successful in 
determining protection in the swine and poultry industries. 
It is reasonable to assume, therefore, that same techni-
ques such as the one employed in this study could be 
applied to companion animals. Serological testing of 
post-vaccination immunity can allow for the establishment 
of more cost-effective vaccines and vaccination schedu-
les, elimination of unnecessary revaccinations and clients 
could be provided with a scientifically based rationale for 
use of vaccines. The end result therefore would be an 
improvement in the overall health of animals. In this stu-
dy, the diagnostic value of using the immunoblot ELISA 
assay for the rapid detection of CPV and CDV IgG is in 
total agreement with what was reported in previous stu-
dies. Instances where IgG antibody titres are low in dogs 
previously vaccinated, revaccination becomes necessary. 
Where IgG levels are low in conditions of natural infect-
ions as occurs in CPV infected dogs, accurate early diag-
nosis and prompt treatment of cases become very easy. 
This work has set out to allay the fears on the use of 
this commercial multivalent modified-live vaccine by vete-
rinarians and other animal health providers in Nigeria. 
Despite the efficacy of this vaccine in providing post-
vaccination immunity to dogs as confirmed in this study, 
we still recommend that efforts be made by relevant 
stake-holders like the Universities, Research Institutes, 
NGOs and other government agencies to fund and 
intensify research into the development of either local 
monovalent or multivalent modified-live vaccines for com-
panion animals in Nigeria. This will go a long way in 
providing better quality vaccines developed from local 
strains of infectious agents and averting problems usually 
associated with the maintenance of cold chains such as 
poor handling, defective storage facilities and inconsis-
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